A retrospective case study of laryngeal edema causing airway obstruction immediately post COVID-19 vaccination
Keywords:Laryngealedema, Vaccination, Sabah, COVID-19
Background: Laryngeal edema is defined as abnormal accumulation of fluid and swelling in the tissues of the larynx commonly associated with laryngeal injuries and allergic causes. The objective of this study is for the prompt recognition and management of laryngeal edema caused by an anaphylaxis reaction after receiving the COVID-19 vaccination from Pfizer-BioNTech, which is extremely important in view of its high morbidity and mortality rate.
Methods: A retrospective case reviews was conducted for all health care workers in Sabah who were administered COVID-19 vaccination from Pfizer-BioNTech from February 2021-April 2021.
Results: The mean age of study population in present study was found to be 33 years. Total of 42 patients were admitted during the period of 6 weeks out of 5000 health care workers who were vaccinated. Females constituted 64.3% of the study population while males constituted 35.7%. The clinical signs of laryngeal edema were dysphagia; the sensation of a lump in the throat; a feeling of tightness in the throat; voice changes, including hoarseness and roughness; and dyspnea within the period of 3 to 5 minutes post Pfizer COVID-19 vaccination. All patients received appropriate management using standard guidelines.
Conclusions: The administration of the COVID-19 vaccination from Pfizer-BioNTech is life-threatening, however, its identification may aid in prompt emergency management in the future. Referral to an otorhinolaryngologist is necessary for patients who experience immediate or severe reactions.
Patterson R, Schatz M. Factitious allergic emergencies: Anaphylaxis and laryngeal “edema”. J Allergy Clin Immunol. 1975;56(2)152-9.
Kelso JM, Greenhawt MJ, Li JT. Adverse reactions to vaccinations practice parameter 2012 update. J Allergy Clin Immunol. 2012;130(1):25-43.
Colice GL, Stukel TA, Dain B. Laryngeal complications of prolonged intubation. Chest. 1989;96:877-84.
World Health Organisation (WHO). COVID-19 vaccinations. 2021. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccinations. Accessed on 2021 Feb, 12.
Hussain K, Kawsar A, Weir J, Au L, Turajlic S, Larkin J, Fearfield L. Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: a second hit? Clin experimental Dermatol. 2021
Centers for Disease Control and Prevention. Selected adverse events reported after COVID‐19 vaccination. Available at: cdc.gov/coronavirus/2019‐ncov/vaccinations/safety/adverse‐events.html. Accessed on 2021 Aug 2.
Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccinations in the US-December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101-2.
Tanabe M, Hikone M, Sugiyama K, Hamabe Y. Systemic capillary leak syndrome complicated by laryngeal edema after severe acute respiratory syndrome coronavirus 2 vaccination. Acute Med Surg. 2021;8(1):e700.
Mayfield J, Bandi S, Ganti L, Rubero J. Anaphylaxis after Moderna COVID-19 vaccine. Ther Adv Vaccines Immunother. 2021;9:25151355211048418.
Khemani RG, Randolph A, Markovitz B. Corticosteroids for the prevention and treatment of post-extubation stridor in neonates, children and adults. Cochrane Database Syst Rev. 2009;8.
Ohki M, Baba Y, Kikuchi S, Ohata A, Tsutsumi T, Tanaka S et al. Potentially lethal pharyngolaryngeal edema with dyspnea in adult patients with mumps: A series of 5 cases. 2015;94(4-5):184-6.
Zhao Y, Sun S, Li X. Drug-induced anaphylaxis in China: a 10-year retrospective analysis of the Beijing Pharmacovigilance Database. Int J Clin Pharm. 2018;40:1349-58.
Dirceu S. Anaphylaxis in Latin America: a report of the online Latin American survey on anaphylaxis (OLASA). Clinics. 2011;66(6):943-7.
Darmon JY, Rauss A, Dreyfuss D, Bleichner G, Elkharrat D, Schlemmer B et al. Evaluation of risk factors for laryngeal edema after tracheal extubation in adults and its prevention by dexamethasone. A placebo-controlled, double-blind, multicenter study. Anesthesiology. 1992;77(2):245-51.
Ho LI, Harn HJ, Lien TC. Postextubation laryngeal edema in adults risk factor evaluation and prevention by hydrocortisone. Intensive Care Med. 1996;22:933-6.
NA. Nanomedicine and the COVID-19 vaccinations. Nat Nanotechnol. 2020;15:963.
United States Food and Drug Administration (FDA). FDA takes key action in fight against covid-19 by issuing emergency use authorization for first COVID-19 vaccination. 2020. Available at: https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19. Accessed on 2021 February 12.
Cox F, Khalib K, Conlon N. PEG That Reaction: A Case Series of Allergy to Polyethylene Glycol. J Clin Pharmacol. 2021;61(6):832-5.
Chiranthi L, Priyadarshani G, Suranjith S. Corticosteroids in management of anaphylaxis; a systematic review of evidence. Europ Ann Allergy Clin Immunol. 2017;49:196.
Choo KJ, Simons FE, Sheikh A. Glucocorticoids for the treatment of anaphylaxis. Cochrane DB Syst Rev. 2012;(4):CD007596.